Paradigm patent rejection, page-31

First 31 Last

Share
Profile

Follow
Torpy

1,576 Posts.

628

07/03/22

10:23

Post #: 60024731
Share

Originally posted by greatgump: ↑

There are 3 patent families:
1. PPS and BML: This patent has been issued. Provides protection until 2032. In January 2018, Paradigm Biopharmaceuticals Ltd announced that it had been granted a European patent for the treatment of Bone Marrow Edema Lesions with Pentosan Polysulfate Sodium (PPS), and throughout 2018 has validated the patent in European member states. The European registration enhances Paradigm’s already strong patent position, adding to previously granted registrations in Australia, the United States, Japan, China, Canada, Taiwan, Singapore and other countries across the Asia-Pacific.

In order as new things have been discovered we have added additional patents.
2. PPS, BML and improved knee function: This is the one just rejected
3. PPS and NGF (i.e. pain): This still going through evaluation but could be rejected

Potential New Patent Families: Study OA 008 for DMOAD should inform new patent applications

The Bene exclusive supply agreement for 25 years just adds another powerful layer commercial protection. Bene is the only FDA approved supplier of PPS and no generic has been made as there are complex steps to manufacture it and Bene own the IP for specific manufacturing custom built procedures.

Elmiron (oral PPS) sold by J&J came off patent in January 2010. But due to their exclusive supply agreement with Bene no generic competitor has been able to enter the market.

So for going commercial negotiations for OA having as many patents and exclusivity supply with Bene is the best outcome. I think it is that basic

Expand

yes that’s how I understand it. Rolling patent applications to extend the life. We are currently covered globally til 2032

PAR Price at posting: $1.04 Sentiment: None Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

REA

UK-based Rightmove knocks back REA Group's acquisition proposal

MAY

HotCopper users liking Melbana Energy's news it's becoming an oil producer; shares jump +47%

LU7

Lithium Universe 'dream team' ready to step into the demand-supply breach in Canada

S&P 500 futures dip during non-deciding Trump-Harris Debate; bullish for energy

PIQ

Proteomics ends deal with Sonic Healthcare for US commercialisation of kidney disease test

There are more pages in this discussion • 57 more messages in this thread...

First 31 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 24.5¢		Change -0.005(2.00%)		Mkt cap ! $85.70M

Open	High	Low	Value	Volume
25.0¢	25.5¢	24.0¢	$187.1K	755.0K

Buyers (Bids)

No.	Vol.	Price($)
2	47906	24.5¢

Sellers (Offers)

Price($)	Vol.	No.
25.0¢	13363	1

View Market Depth

No.	Vol.	Price($)
2	47906	0.245
3	82048	0.240
2	32293	0.235
8	110599	0.230
7	89672	0.225

Price($)	Vol.	No.
0.250	13363	1
0.255	34148	4
0.260	6415	2
0.270	19081	2
0.275	13636	2

Last trade - 16.10pm 11/09/2024 (20 minute delay)

PAR (ASX) Chart

Paradigm patent rejection, page-31

UK-based Rightmove knocks back REA Group's acquisition proposal

HotCopper users liking Melbana Energy's news it's becoming an oil producer; shares jump +47%

Lithium Universe 'dream team' ready to step into the demand-supply breach in Canada

S&P 500 futures dip during non-deciding Trump-Harris Debate; bullish for energy

Proteomics ends deal with Sonic Healthcare for US commercialisation of kidney disease test

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Paradigm patent rejection, page-31

Top Stories

UK-based Rightmove knocks back REA Group's acquisition proposal

HotCopper users liking Melbana Energy's news it's becoming an oil producer; shares jump +47%

Lithium Universe 'dream team' ready to step into the demand-supply breach in Canada

S&P 500 futures dip during non-deciding Trump-Harris Debate; bullish for energy

Proteomics ends deal with Sonic Healthcare for US commercialisation of kidney disease test

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News